@kidneymo profile picture
Mohamed Hassanein 🇪🇬 محمد حسنين @kidneymo

Kidney Doctor 𖠗⎜Lifelong Learner & Educator⎜@CleClinicKidney @UMMCneph alumnus⎜@GlomCon⎜@onconephsociety⎜Son of a legendary man⎜Posts are NOT medical advice

Joined December 2019
  • Tweets 2,558
  • Following 1,767
  • Followers 4,490
425 Photos and videos
Today marks my last day as a nephrologist and #IMG in the United States of America. I've learned the hard way that life is too short and that my happiness lies within my family's happiness. So, I'm returning permanently to my home country, Egypt. (🧵 1)
258
364
5,684
560,508
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Nephrology Congress@NephrologyProfs
Jun 14
Yesterday at #GN2026, Day 2 featured sessions on uncontrolled gout, women with glomerular diseases, glomerular disease in the elderly, EMPA-KIDNEY, and ASi SGLT2 strategies in CKD. Join us today for Conference Day 3. #Nephrology #CKD #KidneyHealth
1
2
144
Proud to represent my beloved institution and country Egypt 🇪🇬 in the 6th Glomerulonephritis Conference in Dubai, UAE. Thank you Dr. Ahmed Ewaida for the kind invitation. Your efforts in advancing the care of patients with GN in the Middle East are commendable. @NephrologyProfs @EMANTSociety
12
607
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Sara Almutar
@s_almutar
Jun 13
Dr Mohamed Hassanein presenting an excellent talk on pregnancy in women with glomerular diseases at the 6th Glomerulonephritis conference in Dubai🌟 @kidneymo
3
2
23
1,641
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
American Society of Onconephrology@onconephsociety
Jun 11
Join us for an amazing Onconephrology educational series by the experts Dr. Idris Boudhabhay and Dr Ala Abudayyeh ✅Immune Check Point Inhibitor Associated AIN: Identification of Neutrophil-Rich Subtype ✅Friday, June 19th EDT @PAmarapurkar @SabineKaram6
5
8
375
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Nephrology Congress@NephrologyProfs
Jun 12
Happening Now at #GN2026 The Nephropathology Workshop is officially underway, beginning with a warm welcome and introduction by Dr. Ahmed Ewaida, Scientific Committee Chairman of the 6th Glomerulonephritis Conference 2026. Dubai, UAE | 12–14 June 2026 glomerulonephritis.org
1
1
2
134
Looking forward to meeting all my smart cardiology colleagues at Cardioalex, the biggest cardiology conference in the middle east. June 11 10:30 am, West Arena Hall. Biblotheca Alexandrina. Alexandria, Egypt. #Cardiorenal
4
254
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Noroژa | Niloufar Ebrahimi@n0r0zha
Jun 9
Today at #PKDMDP, Dr. Chebib taught us about emerging therapies and the clinical trial landscape in ADPKD. @GlomCon @fouadchebib @MarieTherese998
5
18
1,192
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Sol Carriazo, Neph.@Nefrontera
Jun 9
Today we had an outstanding talk about clinical trials in ADPKD by Dr. @fouadchebib from Mayo Clinic Florida at @GlomCon PKD-MDP. -Consideration for Tolvaptan initiation and referral for possible clinical trials. -Key Milestones in ADPKD and clinical trials
4
13
995
Don't miss this important session, Friday June 12 on Fundamentals of Renal Transplant Pathology by fantastic @MayoClinicNeph faculty: Speaker:@sam_albadri Moderator:@AttiehRose Time Zones and Meeting Details below in shared post below: ⬇️
GlomCon Arabia@glomconarabia
Jun 9
Join us next Friday, June 12, in our next @GlomCon Arabia Seminar as @sam_albadri presents a lecture on "Fundamentals of Renal Transplant Pathology," moderated by @AttiehRose Timezones and Meeting details⬇️ glomcon.zoom.us Meeting ID: 884 4208 1901 Passcode: 100499
3
5
577
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Sandra Herrmann MD, FASN@HerrmannMd
Jun 5
Congratulations Dr @fervenzaf and team: Obinituzumab vs Tacrolimus for MN @NEJM @MayoClinicNeph 👏👏
NEJM
@NEJM
Jun 5
Presented at #ERA26: In this 104-week trial involving patients with primary membranous nephropathy, the type II anti-CD20 antibody obinutuzumab was superior to the calcineurin inhibitor tacrolimus in inducing complete remission. Full phase 3 MAJESTY trial results: nej.md/4dZsVPD @ERAkidney
A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.

ALT A line graph from an article published in the New England Journal of Medicine compares obinutuzumab and tacrolimus in treating primary membranous nephropathy over 104 weeks. The y-axis represents the percentage of patients relapse‑free, while the x-axis represents weeks. The graph shows two lines, one for obinutuzumab and another for tacrolimus. The image mentions the European Renal Association Congress at the top.

1
18
90
9,152
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Amer Zeidan عامر زيدان
@Dr_AmerZeidan
Jun 3
A moment of pride! A co-first author in the best journal in medicine for a clinical trial that resulted in FDA approval in the USA and is changing how we treat acute myeloid leukemia #AMLsm. Congratulations to all the authors لحظة فخر! باحث أول مشارك في أفضل مجلة علمية في الطب لتجربة إكلينيكية أدت إلى موافقة إدارة الغذاء والدواء الأمريكية وتغير الطريقة التي نعالج بها اللوكيميا النخاعية الحادة.
NEJM
@NEJM
Jun 3
In a phase 1–2 trial involving patients with acute myeloid leukemia, the use of oral decitabine–cedazuridine with venetoclax induced a complete response in 47% of patients, with expected myelosuppressive effects. Full ASCERTAIN-V trial results: nej.md/4fpoGzl Try asking AI Companion to break this article down into teaching points for you.
Chart titled "Percentage of Patients Who Received Venetoclax for 28 Days" from "All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia" published in the New England Journal of Medicine. The chart compares percentages across three cycles.

ALT Chart titled "Percentage of Patients Who Received Venetoclax for 28 Days" from "All-Oral Treatment of Newly Diagnosed Acute Myeloid Leukemia" published in the New England Journal of Medicine. The chart compares percentages across three cycles.

46
56
439
50,916
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Hans-Joachim Anders@hjanders_hans
May 19
Now online in @NDTsocial Anti-Obinutuzumab Antibodies in Primary Membranous Nephropathy 🧐30.4% of PMN pts with OBI tested for AOA but without statistically significant difference between AOA status and treatment outcomes ▶️academic.oup.com/ndt/article…
4
19
46
2,344
If you are a nephrology fellow do not miss the opportunity to train and learn from the best ⬇️. @kdjhaveri @HofstraKidney
Kenar Jhaveri
@kdjhaveri
May 19
Apply for the GN-Onconephrology 1 year advanced fellowship for 2027 -2028 nejmcareercenter.org/job/991… @HofstraKidney
4
1,073
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Kenar Jhaveri
@kdjhaveri
May 14
Tweetorial on Histotripsy related AKI @renalmyeloma @HofstraKidney 1) What is histotripsy? Histotripsy is a non-invasive, FDA-approved (as of late 2023) cancer treatment that uses focused ultrasound waves to destroy liver tumors without incisions, radiation, or chemotherapy.pmc.ncbi.nlm.nih.gov/article… @onconephsociety
1
18
39
2,625
Truly enjoyed speaking at the National Institute of Urology and Nephrology’s Yearly Summit of Nephrology and Urology Conference. Thank you Dr. @drmszaki73 for the kind invitation.
14
476
Mohamed Hassanein 🇪🇬 محمد حسنين retweeted
Ahmed Abdelhamid@AhmedOsman1987
May 11
I am thrilled to be in Prague this week for the 28th European Congress of Endocrinology, the largest gathering of endocrinologists in Europe and the world. ​I’m especially proud to share that I had 3 research posters accepted for presentation this year. #ECE2026 #Endocrinology
1
2
11
669
Impact of Complement Inhibition is highest where Complement Dysregulation has a Primary Role versus a Secondary Role From Dr. Abdallah Geara's Lecture @glomconarabia on Complement Dysregulation in Glomerular Disease. @GlomCon
10
16
1,437
Load more